MXPA04004797A - Indol-2-carboxamidas como inhibidores del factor xa. - Google Patents
Indol-2-carboxamidas como inhibidores del factor xa.Info
- Publication number
- MXPA04004797A MXPA04004797A MXPA04004797A MXPA04004797A MXPA04004797A MX PA04004797 A MXPA04004797 A MX PA04004797A MX PA04004797 A MXPA04004797 A MX PA04004797A MX PA04004797 A MXPA04004797 A MX PA04004797A MX PA04004797 A MXPA04004797 A MX PA04004797A
- Authority
- MX
- Mexico
- Prior art keywords
- factor
- compounds
- formula
- factor viia
- inhibitors
- Prior art date
Links
- VFHUJFBEFDVZPJ-UHFFFAOYSA-N 1h-indole-2-carboxamide Chemical class C1=CC=C2NC(C(=O)N)=CC2=C1 VFHUJFBEFDVZPJ-UHFFFAOYSA-N 0.000 title 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 title 1
- 108010054265 Factor VIIa Proteins 0.000 abstract 4
- 108010074860 Factor Xa Proteins 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229940012414 factor viia Drugs 0.000 abstract 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Structural Engineering (AREA)
- Materials Engineering (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Nuevos derivados de indol como inhibidores del factor XaLa presente invencion se refiere a compuestos de la formula 1(ver formula 1)en la que R0; R1; R2; R3; R4; R5; R6; R7; Q; V, G Y M poseen los significados indicados en las reivindicaciones; los compuestos de la formula 1 son compuestos valiosos, farmacologicamente activos; estos compuestos ponen de manifiesto un fuerte efecto antitrombotico y son adecuados, por ejemplo, para el tratamiento terapeutico y la profilaxis de trastornos cardiovasculares tales como enfermedades tromboembolicas o restenosis; los compuestos son inhibidores reversibles de las enzimas de la coagulacion sanguinea factor Xa (FXa) y/o factor VIIa) y, en general, pueden ser aplicados en condiciones en las que se encuentra presente una actividad indeseada de factor Xa y/o del factor VIIa; la invencion se refiere ademas, a procedimientos de preparacion de compuestos de la formula 1, a su uso, en particular como ingredientes activos en productos farmaceuticos, y a preparaciones farmaceuticas que los contienen.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01127809A EP1314733A1 (en) | 2001-11-22 | 2001-11-22 | Indole-2-carboxamides as factor Xa inhibitors |
| PCT/EP2002/012500 WO2003044014A1 (en) | 2001-11-22 | 2002-11-08 | Indole-2-carboxamides as factor xa inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04004797A true MXPA04004797A (es) | 2004-08-11 |
Family
ID=8179313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04004797A MXPA04004797A (es) | 2001-11-22 | 2002-11-08 | Indol-2-carboxamidas como inhibidores del factor xa. |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US6906084B2 (es) |
| EP (2) | EP1314733A1 (es) |
| JP (1) | JP4664592B2 (es) |
| KR (2) | KR101033798B1 (es) |
| CN (1) | CN1283638C (es) |
| AR (1) | AR037656A1 (es) |
| AU (1) | AU2002351918B2 (es) |
| BR (1) | BR0214396A (es) |
| CA (1) | CA2467374C (es) |
| CO (1) | CO5580764A2 (es) |
| EC (1) | ECSP045115A (es) |
| HR (1) | HRP20040453A2 (es) |
| HU (1) | HUP0402063A3 (es) |
| IL (2) | IL162105A0 (es) |
| MA (1) | MA27350A1 (es) |
| ME (1) | MEP43008A (es) |
| MX (1) | MXPA04004797A (es) |
| MY (1) | MY131516A (es) |
| NO (1) | NO327466B1 (es) |
| NZ (1) | NZ533044A (es) |
| OA (1) | OA12727A (es) |
| PE (1) | PE20030593A1 (es) |
| PL (1) | PL210986B1 (es) |
| RS (1) | RS40404A (es) |
| RU (1) | RU2299881C2 (es) |
| TN (1) | TNSN04091A1 (es) |
| TW (1) | TWI291950B (es) |
| UA (1) | UA78731C2 (es) |
| WO (1) | WO2003044014A1 (es) |
| ZA (1) | ZA200402945B (es) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0401924A3 (en) * | 2001-11-14 | 2009-07-28 | Schering Corp | Cannabinoid receptor ligands, their use and pharmaceutical compositions containing them |
| US7358268B2 (en) * | 2002-12-04 | 2008-04-15 | Sanofi-Aventis Deutschland Gmbh | Imidazole derivatives as factor Xa inhibitors |
| US7429581B2 (en) | 2002-12-23 | 2008-09-30 | Sanofi-Aventis Deutschland Gmbh | Pyrazole-derivatives as factor Xa inhibitors |
| ES2337254T3 (es) | 2003-02-14 | 2010-04-22 | Glaxo Group Limited | Derivados de carboxamida. |
| US7539725B2 (en) * | 2003-04-03 | 2009-05-26 | Zix Corporation | Auditor system |
| US7223780B2 (en) * | 2003-05-19 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors |
| EP1479675A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Indazole-derivatives as factor Xa inhibitors |
| US7741341B2 (en) | 2003-05-19 | 2010-06-22 | Sanofi-Aventis Deutschland Gmbh | Benzimidazole-derivatives as factor Xa inhibitors |
| EP1479677A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | New indole derivatives as factor xa inhibitors |
| EP1479680A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Azaindole derivatives as Factor Xa inhibitors |
| US7317027B2 (en) * | 2003-05-19 | 2008-01-08 | Sanofi-Aventis Deutschland Gmbh | Azaindole-derivatives as factor Xa inhibitors |
| WO2004108671A1 (en) * | 2003-06-06 | 2004-12-16 | Suven Life Sciences Limited | Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| EP1568698A1 (en) | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrole-derivatives as factor Xa inhibitors |
| EP1571154A1 (en) * | 2004-03-03 | 2005-09-07 | Aventis Pharma Deutschland GmbH | Beta-aminoacid-derivatives as factor Xa inhibitors |
| ATE405549T1 (de) | 2004-06-18 | 2008-09-15 | Biolipox Ab | Zur behandlung von entzündungen geeignete indole |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7772271B2 (en) * | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| AU2005275181A1 (en) | 2004-07-14 | 2006-02-23 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| NZ553329A (en) | 2004-07-22 | 2010-09-30 | Ptc Therapeutics Inc | Thienopyridines for treating hepatitis C |
| FR2874015B1 (fr) * | 2004-08-05 | 2006-09-15 | Sanofi Synthelabo | Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| AU2005299693B2 (en) | 2004-10-26 | 2012-07-05 | Janssen Pharmaceutica, N.V. | Factor Xa compounds |
| DE602005009252D1 (de) * | 2004-12-08 | 2008-10-02 | Bristol Myers Squibb Co | Heterocyclische verbindungen als inhibitoren von faktor viia |
| EP1833819A1 (en) | 2004-12-30 | 2007-09-19 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases |
| FR2880625B1 (fr) * | 2005-01-07 | 2007-03-09 | Sanofi Aventis Sa | Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| DE602005026867D1 (de) | 2005-01-19 | 2011-04-21 | Biolipox Ab | Entzündungshemmende indol-derivate |
| JP5094394B2 (ja) | 2005-04-20 | 2012-12-12 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| FR2888847B1 (fr) | 2005-07-22 | 2007-08-31 | Sanofi Aventis Sa | Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| GB2431927B (en) * | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| US8399442B2 (en) | 2005-12-30 | 2013-03-19 | Astex Therapeutics Limited | Pharmaceutical compounds |
| PT1979314E (pt) * | 2006-01-24 | 2013-03-05 | Lilly Co Eli | Moduladores de indolesulfomamida de receptores de progesterona |
| US7943622B2 (en) | 2006-06-06 | 2011-05-17 | Cornerstone Therapeutics, Inc. | Piperazines, pharmaceutical compositions and methods of use thereof |
| US8435970B2 (en) | 2006-06-29 | 2013-05-07 | Astex Therapeutics Limited | Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea |
| EP3243814B1 (en) | 2007-04-16 | 2018-10-17 | AbbVie Inc. | 7-substituted indole as mcl-1 inhibitors |
| AU2008286946B2 (en) * | 2007-08-10 | 2013-11-21 | H. Lundbeck A/S | Heteroaryl amide analogues |
| TW200920369A (en) | 2007-10-26 | 2009-05-16 | Amira Pharmaceuticals Inc | 5-lipoxygenase activating protein (flap) inhibitor |
| BRPI0820668A2 (pt) * | 2007-12-07 | 2017-08-22 | Abbott Gmbh & Co Kg | Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina |
| CA2710946C (en) * | 2007-12-27 | 2016-05-31 | Abbott Gmbh & Co. Kg | Substituted oxindole-derivatives and the use thereof for the treatment of vasopressin-dependent illnesses |
| MX2010008700A (es) | 2008-02-22 | 2010-08-30 | Hoffmann La Roche | Moduladores de beta-amiloide. |
| MX2010012814A (es) | 2008-05-23 | 2010-12-20 | Amira Pharmaceuticals Inc | Inhibidor de proteina activadora de 5-lipoxigenasa. |
| GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| US8546431B2 (en) | 2008-10-01 | 2013-10-01 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| CA2766100C (en) | 2009-06-29 | 2018-05-22 | Incyte Corporation | Pyrimidinones as pi3k inhibitors |
| WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
| US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
| WO2011130342A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS |
| WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
| ES2764848T3 (es) | 2010-12-20 | 2020-06-04 | Incyte Holdings Corp | N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K |
| WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
| US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
| FR2974576B1 (fr) * | 2011-04-29 | 2013-07-19 | Sanofi Aventis | Derives de n-[(1h-pyrazol-1-yl)aryl]-1h-indole ou 1h- indazole-3-carboxamide, leur preparation et leurs applications en therapeutique |
| KR102131612B1 (ko) | 2011-09-02 | 2020-07-08 | 인사이트 홀딩스 코포레이션 | Ｐｉ３ｋ 억제제로서 헤테로시클릴아민 |
| AU2013226013B2 (en) * | 2012-02-29 | 2016-08-11 | Baruch S. Blumberg Institute | Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation and Their Method of Use |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| DK2970265T3 (en) | 2013-03-15 | 2018-10-01 | Plexxikon Inc | HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| EP3085700B1 (en) * | 2013-12-20 | 2018-10-31 | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China | Novel piperidine carboxamide compound, preparation method, and usage thereof |
| KR102412045B1 (ko) | 2014-05-22 | 2022-06-22 | 놀스 차이나 파마수티칼 컴퍼니., 엘티디. | 혈액응고인자 Xa 억제제로서의 히드라지드 화합물 |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| KR20230026515A (ko) * | 2014-09-10 | 2023-02-24 | 에피자임, 인코포레이티드 | Ｓｍｙｄ 억제제 |
| EP3954685B1 (en) | 2014-12-29 | 2025-08-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof |
| SI3831833T1 (sl) | 2015-02-27 | 2023-03-31 | Incyte Holdings Corporation | Postopki za pripravo inhibitorja PI3K |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| WO2016210294A1 (en) * | 2015-06-25 | 2016-12-29 | Promega Corporation | Thienopyrrole compounds and uses thereof as inhibitors of oplophorus-derived luciferases |
| KR101725451B1 (ko) * | 2016-05-25 | 2017-04-13 | 한국화학연구원 | N-(피페리딘-4-일)-1h-인돌-2-카복스아마이드 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 유로텐신-ⅱ 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| JP6965341B2 (ja) * | 2016-10-18 | 2021-11-10 | シェブロン・オロナイト・テクノロジー・ビー．ブイ． | 船舶用ディーゼル潤滑油組成物 |
| JP7161475B2 (ja) | 2016-12-28 | 2022-10-26 | プロメガ コーポレイション | 官能化ｎａｎｏｌｕｃ阻害剤 |
| EP3592736A1 (en) * | 2017-03-10 | 2020-01-15 | Rutgers, the State University of New Jersey | Indole derivatives as efflux pump inhibitors |
| US10717735B2 (en) | 2017-10-13 | 2020-07-21 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
| IL278889B2 (en) | 2018-06-01 | 2025-11-01 | Incyte Corp | Dosing regimen for the treatment of pi3k related disorders |
| CN116332818B (zh) * | 2021-12-22 | 2023-12-15 | 王喆明 | 四氢吡咯衍生物及其应用 |
| CN116554144B (zh) * | 2022-01-27 | 2025-12-19 | 司马健 | 一种sj系列芳基苯胺类化合物及其制备方法与医药用途 |
| TW202345806A (zh) | 2022-03-31 | 2023-12-01 | 美商艾伯維有限公司 | 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3317524A (en) * | 1965-02-04 | 1967-05-02 | American Home Prod | Substituted 1, 2, 3, 4-tetrahydro-pyrazino[1, 2-a]indoles |
| FR2260332A1 (en) * | 1974-02-12 | 1975-09-05 | Delalande Sa | 1-Phenyl-2-aminocarbonyl-indoles - with respiratory analeptic, antiinflammatory analgesic, vasodilator, diuretic and anti-ulcer activity |
| US4675332A (en) * | 1984-12-10 | 1987-06-23 | Warner-Lambert Company | Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents |
| IE68593B1 (en) * | 1989-12-06 | 1996-06-26 | Sanofi Sa | Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them |
| US5506134A (en) | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
| US5788965A (en) | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
| US5833982A (en) | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
| TW229140B (es) * | 1992-06-05 | 1994-09-01 | Shell Internat Res Schappej B V | |
| FR2703995B1 (fr) * | 1993-04-16 | 1995-07-21 | Sanofi Elf | 5-acylamino 1,2,4-thiadiazoles, leur preparation et compositions pharmaceutiques en contenant. |
| US5518231A (en) | 1993-04-19 | 1996-05-21 | Xerox Corporation | Self adjusting sheet gripping apparatus |
| SI9520044B (sl) | 1994-04-26 | 2004-08-31 | Aventis Pharmaceuticals Inc. | Inhibitorji Xa faktorja |
| CA2224062C (en) * | 1995-06-06 | 2001-09-04 | Pfizer Limited | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
| WO1997003965A1 (en) * | 1995-07-18 | 1997-02-06 | Kyowa Hakko Kogyo Co., Ltd. | Indole derivatives |
| JPH0987282A (ja) * | 1995-09-21 | 1997-03-31 | Kyowa Hakko Kogyo Co Ltd | チアゾール誘導体 |
| WO1997045119A1 (en) * | 1996-05-24 | 1997-12-04 | Novartis Ag | Use of substance p antagonists for treating social phobia |
| FR2763337B1 (fr) * | 1997-05-13 | 1999-08-20 | Sanofi Sa | Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant |
| GB9716657D0 (en) * | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| KR100608472B1 (ko) * | 1997-12-24 | 2006-08-09 | 사노피-아벤티스 도이칠란트 게엠베하 | 인자 Ｘａ의 억제제로서의 인돌 유도체 및 이를 함유하는 약제학적 조성물 |
| AP2000001889A0 (en) | 1998-01-27 | 2000-09-30 | Aventis Pharm Prod Inc | Substituted ozoazaheterocyclyl factor Xa inhibitors. |
| EP0987274A1 (en) | 1998-09-15 | 2000-03-22 | Hoechst Marion Roussel Deutschland GmbH | Factor VIIa Inhibitors |
| JP4241970B2 (ja) * | 1998-10-30 | 2009-03-18 | 中外製薬株式会社 | アミド結合を有するインドール誘導体、及びモノ又はジアザインドール誘導体 |
| JP2001002642A (ja) * | 1999-06-21 | 2001-01-09 | Nippon Nohyaku Co Ltd | 複素環ジカルボン酸ジアミド誘導体及び除草剤並びにその使用方法 |
| JP4829449B2 (ja) | 1999-07-28 | 2011-12-07 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | 置換オキソアザヘテロシクリル化合物 |
| US6486211B1 (en) * | 1999-10-22 | 2002-11-26 | Smithkline Beecham Corporation | Indole compounds |
| AU2001245353A1 (en) | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| US6436965B1 (en) * | 2000-03-02 | 2002-08-20 | Merck Frosst Canada & Co. | PDE IV inhibiting amides, compositions and methods of treatment |
| WO2002000647A1 (en) | 2000-06-23 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
| DE10147672A1 (de) * | 2001-09-27 | 2003-04-10 | Bayer Ag | Substituierte 2,5-Diamidoindole und ihre Verwendung |
| HUP0401924A3 (en) * | 2001-11-14 | 2009-07-28 | Schering Corp | Cannabinoid receptor ligands, their use and pharmaceutical compositions containing them |
| EP1479677A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | New indole derivatives as factor xa inhibitors |
| FR2888847B1 (fr) * | 2005-07-22 | 2007-08-31 | Sanofi Aventis Sa | Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique |
| FR2911604B1 (fr) * | 2007-01-19 | 2009-04-17 | Sanofi Aventis Sa | Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
-
2001
- 2001-11-22 EP EP01127809A patent/EP1314733A1/en not_active Withdrawn
-
2002
- 2002-08-11 UA UA20040604882A patent/UA78731C2/uk unknown
- 2002-11-08 BR BR0214396-8A patent/BR0214396A/pt active Search and Examination
- 2002-11-08 RU RU2004118710/04A patent/RU2299881C2/ru not_active IP Right Cessation
- 2002-11-08 HR HR20040453A patent/HRP20040453A2/xx not_active Application Discontinuation
- 2002-11-08 CN CNB028232488A patent/CN1283638C/zh not_active Expired - Fee Related
- 2002-11-08 MX MXPA04004797A patent/MXPA04004797A/es active IP Right Grant
- 2002-11-08 NZ NZ533044A patent/NZ533044A/en not_active IP Right Cessation
- 2002-11-08 IL IL16210502A patent/IL162105A0/xx unknown
- 2002-11-08 ME MEP-430/08A patent/MEP43008A/xx unknown
- 2002-11-08 PL PL368949A patent/PL210986B1/pl unknown
- 2002-11-08 EP EP02787604.4A patent/EP1451185B1/en not_active Expired - Lifetime
- 2002-11-08 AU AU2002351918A patent/AU2002351918B2/en not_active Ceased
- 2002-11-08 JP JP2003545651A patent/JP4664592B2/ja not_active Expired - Fee Related
- 2002-11-08 CA CA2467374A patent/CA2467374C/en not_active Expired - Fee Related
- 2002-11-08 KR KR1020107003845A patent/KR101033798B1/ko not_active Expired - Fee Related
- 2002-11-08 WO PCT/EP2002/012500 patent/WO2003044014A1/en not_active Ceased
- 2002-11-08 KR KR1020047007838A patent/KR100954508B1/ko not_active Expired - Fee Related
- 2002-11-08 RS YUP-404/04A patent/RS40404A/sr unknown
- 2002-11-08 HU HU0402063A patent/HUP0402063A3/hu unknown
- 2002-11-08 OA OA1200400142A patent/OA12727A/en unknown
- 2002-11-19 PE PE2002001105A patent/PE20030593A1/es not_active Application Discontinuation
- 2002-11-20 TW TW091133782A patent/TWI291950B/zh not_active IP Right Cessation
- 2002-11-20 AR ARP020104452A patent/AR037656A1/es active IP Right Grant
- 2002-11-21 US US10/301,397 patent/US6906084B2/en not_active Expired - Lifetime
- 2002-11-22 MY MYPI20024375A patent/MY131516A/en unknown
-
2004
- 2004-04-19 ZA ZA2004/02945A patent/ZA200402945B/en unknown
- 2004-04-22 MA MA27647A patent/MA27350A1/fr unknown
- 2004-05-20 CO CO04046947A patent/CO5580764A2/es active IP Right Grant
- 2004-05-20 IL IL162105A patent/IL162105A/en not_active IP Right Cessation
- 2004-05-20 EC EC2004005115A patent/ECSP045115A/es unknown
- 2004-05-21 TN TNP2004000091A patent/TNSN04091A1/en unknown
- 2004-06-21 NO NO20042592A patent/NO327466B1/no not_active IP Right Cessation
- 2004-08-26 US US10/926,909 patent/US20050043302A1/en not_active Abandoned
-
2008
- 2008-05-12 US US12/119,013 patent/US20090069565A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04004797A (es) | Indol-2-carboxamidas como inhibidores del factor xa. | |
| TW200510393A (en) | New indole derivatives as factor Xa inhibitors | |
| TW200505914A (en) | Pyrazole-derivatives as factor Xa inhibitors | |
| TW200510400A (en) | Indazole-derivatives as factor Xa inhibitors | |
| IL156588A0 (en) | Oxybenzamide derivatives as factor xa inhibitors | |
| WO2005085239A3 (en) | PYRROLE-DERIVATIVES AS FACTOR Xa INHIBITORS | |
| YU89202A (sh) | Faktor viia inhibitorni derivati (tio)uree, njihovo dobijanje i upotreba | |
| MXPA03011022A (es) | Derivados de urea con actividad antiproteolitica. | |
| YU29702A (sh) | N-gvanidinoalkilamidi, njihovo dobijanje, njihova primena i farmaceutski preparati koji ih obuhvataju | |
| TW200503694A (en) | Triazole-derivatives as factor Xa inhibitors | |
| TW200504027A (en) | Imidazole-derivatives as factor Xa inhibitors | |
| TW200503696A (en) | Benzimidazole-derivatives as factor Xa inhibitors | |
| TNSN05296A1 (en) | AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | |
| JO2467B1 (en) | New indole derivatives as an inhibitor of Xa | |
| TW200716620A (en) | Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status | ||
| FG | Grant or registration |